Krazati slows disease progression in certain patients with lung cancer healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The European Commission has granted conditional marketing authorization to adagrasib for use in adult patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation whose disease progressed following at least 1 prior systemic treatment.
After a re-examination procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the conditional marketing authorization application for adagrasib in the treatment of adult patients with KRAS G12C–mutated advanced non–small cell lung cancer whose disease progressed following at least 1 prior systemic treatment.
Adagrasib monotherapy provided durable efficacy for patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, according to 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial.
Adagrasib has demonstrated intracranial activity among patients with KRAS G12C–mutated non–small cell lung cancer with untreated central nervous system metastases.